News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,864 Results
Type
Article (14955)
Company Profile (299)
Press Release (266604)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79877)
Career Advice (162)
Deals (13340)
Drug Delivery (40)
Drug Development (50719)
Employer Resources (31)
FDA (5846)
Job Trends (5177)
News (145157)
Policy (10082)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (925)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21772)
ALS (124)
Alzheimer's disease (1031)
Antibody-drug conjugate (ADC) (241)
Approvals (6040)
Artificial intelligence (258)
Autoimmune disease (110)
Automation (9)
Bankruptcy (105)
Best Places to Work (4570)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (344)
Cancer (3130)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (217)
CDC (5)
Cell therapy (563)
Cervical cancer (14)
Clinical research (43679)
Collaboration (1148)
Company closure (2)
Compensation (592)
Complete response letters (39)
COVID-19 (1102)
CRISPR (86)
C-suite (550)
Cystic fibrosis (112)
Data (4321)
Denatured (15)
Depression (92)
Diabetes (254)
Diagnostics (1380)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (187)
Drug pricing (48)
Drug shortages (4)
Duchenne muscular dystrophy (214)
Earnings (31653)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51674)
Executive appointments (621)
FDA (7594)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (980)
Gene editing (182)
Generative AI (21)
Gene therapy (487)
GLP-1 (504)
Government (1147)
Grass and pollen (3)
Guidances (166)
Healthcare (6629)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (39)
Indications (66)
Infectious disease (1206)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7349)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1404)
Liver cancer (41)
Longevity (11)
Lung cancer (420)
Lymphoma (248)
Machine learning (24)
Management (7)
Manufacturing (376)
MASH (130)
Medical device (2673)
Medtech (2682)
Mergers & acquisitions (6614)
Metabolic disorders (724)
Multiple sclerosis (103)
NASH (13)
Neurodegenerative disease (229)
Neuropsychiatric disorders (70)
Neuroscience (1951)
Neurotech (1)
NextGen: Class of 2026 (2039)
Non-profit (866)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (131)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (330)
Peanut (43)
People (26666)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15479)
Phase 2 (20296)
Phase 3 (12824)
Pipeline (3247)
Policy (90)
Postmarket research (855)
Preclinical (6541)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (648)
Real estate (1447)
Recruiting (12)
Regulatory (9900)
Reports (19)
Research institute (978)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (182)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2007)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (333)
Venture capital (69)
Weight loss (173)
Women's health (25)
Worklife (2)
Date
Today (13)
Last 7 days (344)
Last 30 days (1127)
Last 365 days (17813)
2026 (1664)
2025 (18102)
2024 (20553)
2023 (22423)
2022 (26846)
2021 (27825)
2020 (23377)
2019 (16260)
2018 (11752)
2017 (13758)
2016 (11849)
2015 (14369)
2014 (10407)
2013 (7493)
2012 (7546)
2011 (7626)
2010 (7434)
Location
Africa (156)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18258)
Australia (3114)
California (7076)
Canada (1837)
China (772)
Colorado (246)
Connecticut (252)
Delaware (235)
Europe (39211)
Florida (905)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (35)
Indiana (160)
Iowa (8)
Japan (222)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5583)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1647)
New Mexico (13)
New York (1762)
North Carolina (828)
North Dakota (6)
Northern California (3473)
Ohio (178)
Oklahoma (11)
Oregon (24)
Pennsylvania (1276)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2808)
Tennessee (40)
Texas (906)
United States (23339)
Utah (96)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (45)
281,864 Results for "achilles therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
Achilles Therapeutics plc announced its financial results for the first quarter ended March 31, 2024, and recent business highlights.
May 8, 2024
·
7 min read
Press Releases
Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca
December 24, 2024
·
4 min read
Press Releases
Achilles Therapeutics Announces Strategic Update
September 19, 2024
·
6 min read
Business
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights
Achilles Therapeutics plc announced its financial results for the fourth quarter and year-ended December 31, 2023, and recent business highlights.
April 4, 2024
·
9 min read
Press Releases
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
November 19, 2024
·
3 min read
Press Releases
Achilles Therapeutics Reports Third Quarter 2024 Financial Results
November 15, 2024
·
5 min read
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced a research collaboration with Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), an mRNA medicines company, to evaluate best-in-class, self-amplifying mRNA (sa-mRNA) personalized cancer vaccines (PCVs) targeting clonal neoantigens.
May 22, 2024
·
8 min read
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference.
February 5, 2024
·
1 min read
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement - May 17, 2024
Achilles Therapeutics plc disclosed that the Company received notice on May 16, 2024 from the Nasdaq Stock Market LLC that the Company is not currently in compliance with the $1.00 minimum bid price requirement for continued listing of the Company’s American Depositary Shares on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rule 5450.
May 17, 2024
·
3 min read
Press Releases
Alafair Biosciences Announces First Patient Enrolled in Multi-Center Study Evaluating VersaWrap® Tendon Protector for Achilles Repair
June 25, 2025
·
3 min read
1 of 28,187
Next
